FCGR3A and neoplasm: The generation of CD16 CAR-T in the present study represented an universal immune cell-based therapeutic approach by simultaneously used with vaccine for vaccine-induced tumor-specific antibodies-directed targeted immune T cell-based anti-tumor immunotherapy.